Skip to main content
Pharmadrug Inc. logo

Pharmadrug Inc. — Investor Relations & Filings

Ticker · PHRX ISIN · CA71716W2040 LEI · 529900PHQPAWL5ITEB39 CSE Manufacturing
Open in API
Filings indexed 475 across all filing types
Latest filing 2021-05-01 Regulatory Filings
Country CA Canada
Listing CSE PHRX

About Pharmadrug Inc.

https://pharmadrug.ca/

Pharmadrug Inc. is a specialty pharmaceutical company focused on the research, development, and commercialization of controlled-substances and natural medicines. The company's primary focus areas include the clinical development of reformulated natural-based medicines aimed at treating unmet needs in oncology and infectious diseases. Additionally, Pharmadrug develops synthetic and biosynthetic formulations of existing drugs, specifically addressing opportunities related to the potential third wave of drug policy reform concerning controlled substances.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CFO. It certifies the review and fair presentation of the annual filings for the financial year ended December 31, 2020. The text explicitly states it is a certification letter and does not contain actual financial statements or detailed financial data. It is primarily an officer certification document related to annual filings, not the filings themselves. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than as the Annual Report (10-K) or other financial reports.
2021-05-01 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of the annual filings including the AIF, annual financial statements, and annual MD&A for the financial year ended December 31, 2020. The document is primarily an officer certification letter and does not contain actual financial data or the full annual report itself. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than the Annual Report (10-K) or other report types. The document length is short (3073 characters) and it is a certification, not the report itself.
2021-05-01 English
News release - English.pdf
Regulatory Filings
2021-04-28 English
News release - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a press release announcing PharmaDrug's advancement in product and clinical development of Cepharanthine for rare cancers and infectious diseases. It discusses agreements, licensing, preclinical and clinical development plans, and forward-looking statements. There are no financial statements, regulatory filings, voting results, or detailed financial data. The content is primarily an update on company activities and development progress, typical of a Capital/Financing Update or general corporate announcement. However, since it focuses on development progress and licensing agreements rather than fundraising or capital structure changes, it fits best under Capital/Financing Update (CAP) as it relates to development and commercialization agreements and progress. The document is not a report, transcript, or regulatory filing, but a corporate announcement about development progress and agreements.
2021-04-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new research collaboration between PharmaDrug Inc. and the University of Michigan to initiate foundational research on DMT. It contains no financial statements, no regulatory filings, no voting results, no management or board changes, no earnings data, and no detailed investor presentation. The content is primarily a corporate announcement about research activities and strategic direction. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial or governance filings. It is a general corporate news announcement, which best fits under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2021-03-16 English
News release - English.pdf
AGM Information Classification · 95% confidence The document is a press release providing an update on the company's upcoming Annual General Meeting (AGM), including details about the date, time, location, and participation instructions. It does not contain the actual AGM materials, minutes, or presentations. The text encourages shareholders to vote using the Management Information Circular available on SEDAR but does not include the circular itself or any detailed AGM content. The document is relatively short (4930 characters) and serves as an announcement about the AGM event rather than the AGM report or materials. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or announcements related to the AGM event itself. Confidence is high as the document clearly focuses on the AGM update and logistics.
2021-03-12 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.